Back to top
more

Haemonetics (HAE)

(Real Time Quote from BATS)

$57.44 USD

57.44
2,769,926

-18.33 (-24.19%)

Updated Aug 7, 2025 01:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Haemonetics (HAE) to Offer Two VASCADE Devices in the EU

by Zacks Equity Research

Haemonetics' (HAE) VASCADE and VASCADE MVP devices help patients attain hemostasis more quickly and with lesser complications.

Zacks Equity Research

Haemonetics (HAE) Up 3.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Retain Haemonetics (HAE) Stock Now

by Zacks Equity Research

Investors are optimistic about Haemonetics' (HAE) better-than-expected results and strong Plasma sales.

Zacks Equity Research

Haemonetics (HAE) Business Recovery Continues, Macro Issues Ail

by Zacks Equity Research

Despite sluggish results of Haemonetics' (HAE) Blood Center business, Whole Blood revenues grow on favorable order timing among distributors in the Asia Pacific and EMEA.

Zacks Equity Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Haemonetics (HAE) Inks Epic Deal to Expand Hospital Business

by Zacks Equity Research

According to Haemonetics (HAE), amid the complex situation of blood supply and staffing shortages, the SafeTrace Tx transfusion management system is set to provide more transfusion safety and efficiency.

Zacks Equity Research

Lantheus Holdings, Inc. (LNTH) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Lantheus Holdings (LNTH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Here's Why Haemonetics (HAE) is a Strong Growth Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Haemonetics (HAE) Hits 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about Haemonetics' (HAE) potential in its Plasma franchise.

Indrajit Bandyopadhyay headshot

4 Stocks to Watch Amid Recovering Medical Products Industry

by Indrajit Bandyopadhyay

Despite the COVID-induced challenges, rising demand for IVD coupled with dependence on AI & Robotics should lend support to the Zacks Medical-Products industry. ZBH, BIO, LNTH and HAE are well-poised to gain from the favorable factors.

Zacks Equity Research

3 Reasons Why Haemonetics (HAE) Is a Great Growth Stock

by Zacks Equity Research

Haemonetics (HAE) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Here's Why Haemonetics (HAE) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Haemonetics (HAE) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Haemonetics (HAE) posts better-than-expected results in Q1 with robust contributions from the Hospital business.

Zacks Equity Research

Haemonetics (HAE) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Haemonetics (HAE) delivered earnings and revenue surprises of 9.43% and 4.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Insulet (PODD) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Insulet (PODD) delivered earnings and revenue surprises of -128.57% and 2.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zimmer Biomet (ZBH) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Zimmer (ZBH) delivered earnings and revenue surprises of 11.66% and 3.31%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Haemonetics (HAE) Hospital Arm Thrives, Gross Margin Rises

by Zacks Equity Research

Strong procedure recovery in the hospital business, the resilience of blood donors in blood centers and rollouts of Persona technology and NexSys aid Haemonetics (HAE).

Zacks Equity Research

Here's Why You Should Retain Haemonetics (HAE) Stock For Now

by Zacks Equity Research

Investors are optimistic about Haemonetics' (HAE) robust performances across the Hospital and Plasma businesses.

Zacks Equity Research

Haemonetics (HAE) Up 28.2% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Haemonetics (HAE) Gains on Procedure Recovery Amid Cost Woes

by Zacks Equity Research

A strong procedure recovery in the hospital business, the resilience of blood donors in blood centers, and rollouts of Persona technology and NexSys aid Haemonetics (HAE).

Zacks Equity Research

Here's Why Investors Should Retain Haemonetics (HAE) For Now

by Zacks Equity Research

Investors are optimistic about Haemonetics's (HAE) better-than-expected results and robust segmental performance.

Zacks Equity Research

Haemonetics (HAE) Q4 Earnings Top Estimates, Gross Margin Up

by Zacks Equity Research

Robust performance by Plasma and Hospital businesses drove Haemonetics' (HAE) revenues in the fiscal fourth quarter.

Zacks Equity Research

Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Haemonetics (HAE) delivered earnings and revenue surprises of 8.33% and 2.56%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Trina Mukherjee headshot

3 Medical Product Stocks Set to Beat on Earnings This Season

by Trina Mukherjee

Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how CGC, HAE and ALC are poised ahead of their earnings releases.

Zacks Equity Research

Clover Health (CLOV) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Clover Health's (CLOV) first-quarter results are likely to reflect benefits from Clover Assistant management.